MX2008012495A - Formulaciones de dosis baja de diclofenaco y beta-ciclodextrina. - Google Patents
Formulaciones de dosis baja de diclofenaco y beta-ciclodextrina.Info
- Publication number
- MX2008012495A MX2008012495A MX2008012495A MX2008012495A MX2008012495A MX 2008012495 A MX2008012495 A MX 2008012495A MX 2008012495 A MX2008012495 A MX 2008012495A MX 2008012495 A MX2008012495 A MX 2008012495A MX 2008012495 A MX2008012495 A MX 2008012495A
- Authority
- MX
- Mexico
- Prior art keywords
- diclofenac
- dose
- compound
- pharmaceutical composition
- dosage
- Prior art date
Links
- 229960001259 diclofenac Drugs 0.000 title claims abstract description 75
- 229920000858 Cyclodextrin Polymers 0.000 title claims abstract description 25
- 235000011175 beta-cyclodextrine Nutrition 0.000 title claims abstract description 18
- 239000001116 FEMA 4028 Substances 0.000 title claims abstract description 16
- 229960004853 betadex Drugs 0.000 title claims abstract description 16
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 title claims description 51
- 239000000203 mixture Substances 0.000 title description 47
- 238000009472 formulation Methods 0.000 title description 44
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 title description 9
- -1 diclofenac compound Chemical class 0.000 claims abstract description 41
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 32
- 230000036592 analgesia Effects 0.000 claims abstract description 23
- 208000002193 Pain Diseases 0.000 claims description 49
- 230000036407 pain Effects 0.000 claims description 46
- 239000003814 drug Substances 0.000 claims description 18
- 241000124008 Mammalia Species 0.000 claims description 14
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 10
- 229960001193 diclofenac sodium Drugs 0.000 claims description 9
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical group [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 claims description 9
- 239000003381 stabilizer Substances 0.000 claims description 5
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical group OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000000034 method Methods 0.000 abstract description 11
- 230000000694 effects Effects 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 231100000419 toxicity Toxicity 0.000 description 10
- 230000001988 toxicity Effects 0.000 description 10
- 238000001990 intravenous administration Methods 0.000 description 9
- 239000000902 placebo Substances 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 9
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 7
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 229940038424 dyloject Drugs 0.000 description 5
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000003466 anti-cipated effect Effects 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 229960004752 ketorolac Drugs 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000004550 Postoperative Pain Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940097362 cyclodextrins Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000005067 remediation Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 241000272470 Circus Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000005298 acute pain Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229960004384 ketorolac tromethamine Drugs 0.000 description 2
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 206010004663 Biliary colic Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 239000004381 Choline salt Substances 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 241000777300 Congiopodidae Species 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 206010038419 Renal colic Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- WQZGKKKJIJFFOK-UHFFFAOYSA-N alpha-D-glucopyranose Natural products OCC1OC(O)C(O)C(O)C1O WQZGKKKJIJFFOK-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000019417 choline salt Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012972 dimethylethanolamine Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- ZEKANFGSDXODPD-UHFFFAOYSA-N glyphosate-isopropylammonium Chemical compound CC(C)N.OC(=O)CNCP(O)(O)=O ZEKANFGSDXODPD-UHFFFAOYSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- RZSCFTDHFNHMOR-UHFFFAOYSA-N n-(2,4-difluorophenyl)-2-[3-(trifluoromethyl)phenoxy]pyridine-3-carboxamide;1,1-dimethyl-3-(4-propan-2-ylphenyl)urea Chemical compound CC(C)C1=CC=C(NC(=O)N(C)C)C=C1.FC1=CC(F)=CC=C1NC(=O)C1=CC=CN=C1OC1=CC=CC(C(F)(F)F)=C1 RZSCFTDHFNHMOR-UHFFFAOYSA-N 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 210000004357 third molar Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78648606P | 2006-03-28 | 2006-03-28 | |
| PCT/US2007/064678 WO2007112272A2 (en) | 2006-03-28 | 2007-03-22 | Formulations of low dose diclofenac and beta-cyclodextrin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2008012495A true MX2008012495A (es) | 2009-01-07 |
Family
ID=38541808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2008012495A MX2008012495A (es) | 2006-03-28 | 2007-03-22 | Formulaciones de dosis baja de diclofenaco y beta-ciclodextrina. |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US8580954B2 (https=) |
| EP (3) | EP2004203A4 (https=) |
| JP (3) | JP5823093B2 (https=) |
| KR (5) | KR20080112285A (https=) |
| CN (2) | CN101410123A (https=) |
| AU (1) | AU2007230716B2 (https=) |
| BR (1) | BRPI0709409A2 (https=) |
| CA (1) | CA2647348A1 (https=) |
| IL (2) | IL194185A (https=) |
| MX (1) | MX2008012495A (https=) |
| WO (1) | WO2007112272A2 (https=) |
| ZA (1) | ZA200808115B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8580954B2 (en) * | 2006-03-28 | 2013-11-12 | Hospira, Inc. | Formulations of low dose diclofenac and beta-cyclodextrin |
| KR20090010953A (ko) * | 2006-03-28 | 2009-01-30 | 자블린 파머슈티칼스 인코포레이티드 | 저 복용량의 비-스테로이드성 항염증성 약물 및 베타-사이클로덱스트린 제형 |
| US9550827B2 (en) | 2007-10-19 | 2017-01-24 | The Regents Of The University Of California | Methods for ameliorating and preventing central nervous system inflammation |
| EP2632553B1 (en) | 2010-10-28 | 2020-01-01 | Pacira Pharmaceuticals, Inc. | A sustained release formulation of a non-steroidal anti-inflammatory drug |
| MY166036A (en) * | 2011-07-20 | 2018-05-21 | Hospira Inc | Methods of treating pain |
| US20140275261A1 (en) | 2013-03-15 | 2014-09-18 | Dr. Reddy's Laboratories, Inc. | Diclofenac parenteral compositions |
| CN107126418B (zh) * | 2016-02-25 | 2020-05-29 | 江苏思邈医药科技有限公司 | 供注射用双氯芬酸钠药物组合物及其制备方法 |
| EP3541815A4 (en) | 2016-11-18 | 2020-07-15 | Pacira Pharmaceuticals, Inc. | ZINC MELXICAM COMPLEX MICROPARTICLE MULTIVESICULAR LIPOSOME FORMULATIONS AND METHODS OF MAKING THE SAME |
| US11110073B2 (en) | 2017-03-24 | 2021-09-07 | Cadila Healthcare Limited | Storage stable aqueous injectable solution comprising diclofenac |
| GB201720992D0 (en) * | 2017-12-15 | 2018-01-31 | Hooper Mark | A medical use |
| WO2021048748A1 (en) | 2019-09-09 | 2021-03-18 | Ftf Pharma Private Limited | Pharmaceutical formulations comprising diclofenac |
| US11707443B2 (en) | 2019-09-26 | 2023-07-25 | Rk Pharma Inc. | Storage stable aqueous parenteral solutions comprising diclofenac |
| US20240382597A1 (en) * | 2021-12-31 | 2024-11-21 | LIVIONEX, Inc. | Formulations of anti-inflammatory agents comprising msm with enhanced solubility in water |
Family Cites Families (137)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5984821U (ja) | 1982-11-30 | 1984-06-08 | 日新電機株式会社 | 積層コイル |
| JPS59188644A (ja) | 1983-04-09 | 1984-10-26 | Fuji Photo Film Co Ltd | 画像形成方法 |
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| DE3446873A1 (de) | 1984-12-21 | 1986-07-10 | Merckle Gmbh | Fluessige diclofenac-zubereitungen |
| GB8506792D0 (en) | 1985-03-15 | 1985-04-17 | Janssen Pharmaceutica Nv | Derivatives of y-cyclodextrin |
| US5785989A (en) | 1985-05-01 | 1998-07-28 | University Utah Research Foundation | Compositions and methods of manufacturing of oral dissolvable medicaments |
| US6407079B1 (en) | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
| JPS62138437U (https=) | 1986-02-26 | 1987-09-01 | ||
| YU43290B (en) | 1986-11-13 | 1989-06-30 | Lek Tovarna Farmacevtskih | Process for preparing inclusioned complex of ibuproxane with beta-cyclodextrine |
| JPH0616547Y2 (ja) | 1986-12-16 | 1994-05-02 | ヒゲタ醤油株式会社 | 諸味揚槽用濾布 |
| US5690954A (en) | 1987-05-22 | 1997-11-25 | Danbiosyst Uk Limited | Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material |
| US5017566A (en) | 1987-12-30 | 1991-05-21 | University Of Florida | Redox systems for brain-targeted drug delivery |
| US5002935A (en) | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| EP0335545B2 (en) | 1988-03-29 | 1998-09-23 | University Of Florida | Pharmaceutical formulations for parenteral use |
| JP2575460B2 (ja) * | 1988-05-12 | 1997-01-22 | 東京田辺製薬株式会社 | ダナゾール−シクロデキストリン包接化合物 |
| MY106598A (en) | 1988-08-31 | 1995-06-30 | Australian Commercial Res & Development Ltd | Compositions and methods for drug delivery and chromatography. |
| IT1227626B (it) | 1988-11-28 | 1991-04-23 | Vectorpharma Int | Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione |
| CH679277A5 (https=) | 1989-02-09 | 1992-01-31 | Sandoz Ag | |
| IT1241417B (it) | 1990-03-06 | 1994-01-14 | Vectorpharma Int | Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione |
| IT1243342B (it) | 1990-07-13 | 1994-06-10 | Farcon Ag | Composizioni farmaceutiche orali liquide ad attivita' antiinfiammatoria |
| JP3765579B2 (ja) | 1990-08-24 | 2006-04-12 | イーデーエーアー アーゲー | 作用物質投与用超微小滴状調剤 |
| EP1004318A3 (en) | 1991-06-21 | 2002-08-07 | Takeda Chemical Industries, Ltd. | Cyclodextrin composition |
| DE4207922A1 (de) | 1992-03-13 | 1993-09-23 | Pharmatech Gmbh | Wasserloesliche einschlussverbindungen und verfahren zu deren herstellung |
| IT1255522B (it) | 1992-09-24 | 1995-11-09 | Ubaldo Conte | Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita' |
| US5811547A (en) | 1992-10-14 | 1998-09-22 | Nippon Shinyaju Co., Ltd. | Method for inducing crystalline state transition in medicinal substance |
| US5389681A (en) | 1992-10-22 | 1995-02-14 | Ciba-Geigy Corporation | Parenteral solutions for diclofenac salts |
| IT1256386B (it) | 1992-11-13 | 1995-12-04 | Luigi Boltri | Composizioni farmaceutiche comprendenti un farmaco,una sostanza polimerica reticolata,un olio ed un agente tensioattivo |
| AU6971294A (en) | 1993-06-08 | 1995-01-03 | Novartis Ag | Process for the preparation of an oral solid dosage form containing diclofenac |
| IT1264696B1 (it) | 1993-07-09 | 1996-10-04 | Applied Pharma Res | Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata |
| GB9316580D0 (en) | 1993-08-10 | 1993-09-29 | Smithkline Beecham Plc | Pharmaceutical composition |
| US5866162A (en) | 1993-08-10 | 1999-02-02 | Smithkline Beecham P.L.C. | Pharmaceutical composition containing a drug/β-cyclodextrin complex in combination with an acid-base couple |
| GB9318880D0 (en) | 1993-09-11 | 1993-10-27 | Smithkline Beecham Plc | Pharmaceutical composition |
| IL111184A (en) | 1993-10-08 | 2000-08-13 | Farmarc Nederland B V Of Cito | Crystalline inclusion complex of diclofenac with unsubstituted beta-cyclodextrin |
| US5540930A (en) | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
| WO1995013794A1 (en) | 1993-11-18 | 1995-05-26 | Nippon Shinyaku Co., Ltd. | Process for producing stable medicinal composition, and pharmaceutical preparation |
| ZA949182B (en) | 1993-12-02 | 1995-07-26 | South African Druggists Ltd | Pharmaceutical composition |
| US5464633A (en) | 1994-05-24 | 1995-11-07 | Jagotec Ag | Pharmaceutical tablets releasing the active substance after a definite period of time |
| JPH10500982A (ja) | 1994-05-27 | 1998-01-27 | ファーマーク、ネダーランド、ベスローテン、フェンノートシャップ | 医薬組成物 |
| WO1996011003A1 (en) | 1994-10-10 | 1996-04-18 | Novartis Ag | Ophthalmic and aural compositions containing diclofenac potassium |
| ZA959469B (en) | 1994-11-15 | 1996-05-15 | South African Druggists Ltd | Pharmaceutical composition |
| ATE215821T1 (de) | 1995-01-20 | 2002-04-15 | Wakamoto Pharma Co Ltd | Entzündungshemmende augentropfen |
| JP3934705B2 (ja) * | 1995-05-26 | 2007-06-20 | ノバルティス ファーマ株式会社 | サイクロデキストリン組成物 |
| US5747058A (en) | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
| US5821237A (en) | 1995-06-07 | 1998-10-13 | The Procter & Gamble Company | Compositions for visually improving skin |
| IT1276689B1 (it) | 1995-06-09 | 1997-11-03 | Applied Pharma Res | Forma farmaceutica solida ad uso orale |
| AU5774796A (en) | 1995-06-13 | 1997-01-09 | Dyer, Alison Margaret | Pharmaceutical compositions containing lornoxicam and cyclod extrin |
| TW434023B (en) | 1995-09-18 | 2001-05-16 | Novartis Ag | Preserved ophthalmic composition |
| HUP9600758A2 (en) | 1996-03-27 | 1998-03-02 | Cyclolab Ciklodextrin Kutato F | Diclofenac composition of diminished gastrointestinal irritation and enhanced biological resorption |
| FR2751875B1 (fr) | 1996-08-05 | 1998-12-24 | Scr Newpharm | Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation |
| EP0868915A1 (en) | 1997-04-02 | 1998-10-07 | Panacea Biotec Limited | An anti-spasmodic and antiinflammatory composition containing a NSAID, pentifenone and fenpiverinium |
| IT1291362B1 (it) | 1997-05-13 | 1999-01-07 | Vectorpharma Int | Composizioni farmaceutiche multicomponente bifasiche contenenti sostanze atte a modificare la partizione dei principi attivi |
| US6365180B1 (en) | 1998-01-20 | 2002-04-02 | Glenn A. Meyer | Oral liquid compositions |
| EP1049459B1 (en) | 1998-01-20 | 2009-04-22 | Applied Analytical Industries, Inc. | Oral liquid compositions |
| US7772220B2 (en) | 2004-10-15 | 2010-08-10 | Seo Hong Yoo | Methods and compositions for reducing toxicity of a pharmaceutical compound |
| US6365182B1 (en) * | 1998-08-12 | 2002-04-02 | Cima Labs Inc. | Organoleptically pleasant in-mouth rapidly disintegrable potassium chloride tablet |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US7186260B2 (en) | 1999-04-29 | 2007-03-06 | Hyson Morton I | Medicated wrap |
| US6313370B1 (en) | 1999-04-29 | 2001-11-06 | Morton Hyson | Medicated wrap |
| ES2187234A1 (es) * | 1999-04-30 | 2003-05-16 | Lilly Icos Llc | Forma de dosificacion oral para tratar la disfuncion sexual. |
| WO2000071098A1 (en) | 1999-05-24 | 2000-11-30 | Purepac Pharmaceutical Co. | A pharmaceutical composition containing an active agent that is maintained in solid amorphous form and method of making the same |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| ATE283048T1 (de) | 1999-12-08 | 2004-12-15 | Pharmacia Corp | Cyclooxygenase-2 hemmer enthaltende zusammensetzungen mit schnellem wirkungseintritt |
| KR100416242B1 (ko) | 1999-12-22 | 2004-01-31 | 주식회사 삼양사 | 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법 |
| AU4866001A (en) | 2000-03-28 | 2001-10-08 | Farmarc Nederland Bv | Alprazolam inclusion complexes and pharmaceutical compositions thereof |
| WO2001098329A1 (en) | 2000-06-22 | 2001-12-27 | Theravance, Inc. | Polyhydroxy glycopeptide derivatives |
| PE20020146A1 (es) | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| CN1729002A (zh) | 2000-09-08 | 2006-02-01 | 法玛西雅意大利公司 | 依西美坦作为化学预防剂 |
| EP1219304B1 (de) | 2000-12-28 | 2004-10-20 | Fresenius Kabi Austria GmbH | Stabile Infusionslösung von Diclofenac-Salzen, deren Herstellung und Verwendung |
| EP1219306A1 (en) | 2000-12-29 | 2002-07-03 | Nicox S.A. | Compositions comprising cyclodextrins and NO- releasing drugs |
| JP2004519490A (ja) | 2001-01-26 | 2004-07-02 | フアルマシア・イタリア・エツセ・ピー・アー | エキセメスタンによるホルモン依存性異常症の組合せ治療方法 |
| JP2004525798A (ja) * | 2001-03-28 | 2004-08-26 | バイエル アクチェンゲゼルシャフト | 情報層中に吸光性化合物としてシアニン色素を含有する光学データ記録媒体 |
| US20080220441A1 (en) | 2001-05-16 | 2008-09-11 | Birnbaum Eva R | Advanced drug development and manufacturing |
| US20040137062A1 (en) | 2001-05-25 | 2004-07-15 | Sham Chopra | Chronotherapy tablet and methods related thereto |
| SE0102855D0 (sv) * | 2001-08-27 | 2001-08-27 | Astrazeneca Ab | Method of treatment |
| FR2830017B1 (fr) | 2001-09-27 | 2005-11-04 | Centre Nat Rech Scient | Materiau compose d'au moins un polymere biodegradable et de cyclodextrines |
| EP1443969A2 (en) | 2001-10-18 | 2004-08-11 | Decode Genetics EHF | Non-inclusion cyclodextrin complexes |
| FR2834212B1 (fr) | 2001-12-27 | 2004-07-09 | Besins Int Belgique | Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques |
| BR0307518A (pt) | 2002-02-01 | 2004-12-28 | Shimoda Biotech Pty Ltd | Composição farmacêutica |
| EP1476135A1 (en) | 2002-02-22 | 2004-11-17 | Pharmacia Corporation | Ophthalmic formulation with gum system |
| US6869939B2 (en) | 2002-05-04 | 2005-03-22 | Cydex, Inc. | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| CN1232539C (zh) * | 2002-05-10 | 2005-12-21 | 刘云清 | 有机药物与倍他环糊精衍生物的配合物及其制备方法 |
| AU2003241464A1 (en) | 2002-05-17 | 2003-12-02 | Eisai Co., Ltd. | Compositions and methods using proton pump inhibitors |
| DE60319221T2 (de) | 2002-06-13 | 2009-03-05 | Novartis Ag | Quaternisierte ammoniumcyclodextrinverbindungen |
| FR2842736B1 (fr) | 2002-07-26 | 2005-07-22 | Flamel Tech Sa | Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s) |
| US7148211B2 (en) | 2002-09-18 | 2006-12-12 | Genzyme Corporation | Formulation for lipophilic agents |
| NZ540318A (en) | 2002-10-31 | 2007-09-28 | Umd Inc | Therapeutic compositions for drug delivery to and through covering epithelia |
| BR0316673A (pt) | 2002-11-27 | 2005-10-18 | Pharmacia Corp | Composição lìquida concentrada de valdecoxib |
| US20060134095A1 (en) | 2003-01-27 | 2006-06-22 | Shinobu Ito | Antioxidative composition and composition for external use |
| EP2191846A1 (en) | 2003-02-19 | 2010-06-02 | Rinat Neuroscience Corp. | Method for treating pain by administering a nerve growth factor antagonist and an NSAID and composition containing the same |
| AU2004219595A1 (en) | 2003-03-11 | 2004-09-23 | Qlt Usa Inc. | Formulations for cell- schedule dependent anticancer agents |
| US20050085446A1 (en) | 2003-04-14 | 2005-04-21 | Babu M.K. M. | Fluoroquinolone formulations and methods of making and using the same |
| US20070049552A1 (en) | 2003-04-14 | 2007-03-01 | Babu Manoj M | Fluoroquinolone formulations and methods of making and using the same |
| TW575271U (en) * | 2003-06-25 | 2004-02-01 | Wen-Chin Fan | Three-dimensional picture exhibiting device of image display |
| WO2005042026A1 (ja) | 2003-10-31 | 2005-05-12 | Wakamoto Pharmaceutical Co., Ltd. | 可逆性熱ゲル化水性組成物 |
| US20050095205A1 (en) | 2003-10-31 | 2005-05-05 | Ramesh Krishnamoorthy | Combination of loteprednol etabonate and tobramycin for topical ophthalmic use |
| US20050197303A1 (en) | 2003-10-31 | 2005-09-08 | Bausch & Lomb Incorporated | Combination of loteprednol etabonate and tobramycin for topical ophthalmic use |
| WO2005074887A2 (en) | 2004-01-30 | 2005-08-18 | Rutgers, The State University | Amphiphilic star-like or scorpion-like macromolecules, various compositions and uses thereof |
| KR20050081092A (ko) | 2004-02-12 | 2005-08-18 | 한국과학기술연구원 | 생체적합성 친수성 고분자를 포함하는 콜로이드계 조성물,제형 및 이들의 제조 방법 |
| US20050203115A1 (en) | 2004-03-10 | 2005-09-15 | Sancilio Frederick D. | Narcotic-NSAID ion pairs |
| DK1574221T3 (da) | 2004-03-10 | 2007-07-16 | Shimoda Biotech Pty Ltd | Stabile, injicérbare diclofenacsammensætninger |
| DE102004017351A1 (de) * | 2004-04-08 | 2005-10-27 | Kalle Gmbh | Schlauchförmige Nahrungsmittelhülle mit übertragbarer Innenschicht |
| EP1761283A2 (en) | 2004-06-07 | 2007-03-14 | California Institute Of Technology | Biodegradable drug-polymer delivery system |
| US20090035315A1 (en) | 2004-06-17 | 2009-02-05 | Stephan Christgau | Method of Improving Treatments in Rheumatic and Arthritic Diseases |
| ITMI20041245A1 (it) | 2004-06-22 | 2004-09-22 | Ibsa Inst Biochimique Sa | Composizioni farmaceutiche iniettabnili comprendenti diclofenac sodico e b-ciclodestrina |
| TWI279226B (en) | 2004-07-20 | 2007-04-21 | Schoeller Textil Ag | Dressings which can be applied several times to textile fibres and textile fabrics |
| GB2417900A (en) | 2004-09-11 | 2006-03-15 | Medway Science Technologies Lt | Composition for oral drug delivery |
| BRPI0516308A2 (pt) | 2004-10-04 | 2010-06-15 | Qlt Usa Inc | composição fluida, métodos de tratamento de uma doença ou disfunção, métodos de liberação local ou sistêmica de um agente biológico, implantes, método de formação de um implante, kit de agente biológico e usos de uma composição fluida |
| DE602005027727D1 (de) | 2004-10-15 | 2011-06-09 | Seo Hong Yoo | Zusammensetzungen zur verringerung der toxizität von cisplatin, carboplatin und oxaliplatin |
| WO2006082588A2 (en) | 2005-02-07 | 2006-08-10 | Pharmalight Inc. | Method and device for ophthalmic administration of active pharmaceutical ingredients |
| US7140694B2 (en) * | 2005-03-29 | 2006-11-28 | Steven Mason | Wheel spoke adjuster guard |
| KR101255650B1 (ko) * | 2005-05-04 | 2013-04-16 | 프로노바 바이오파마 너지 에이에스 | 새로운 ｄｈａ 유도체 및 약제로서의 용도 |
| CN103145839A (zh) | 2005-06-30 | 2013-06-12 | Abbvie公司 | Il-12/p40结合蛋白 |
| CA2613875C (en) | 2005-07-04 | 2018-09-25 | Ramu Krishnan | Improved drug or pharmaceutical compounds and a preparation thereof |
| US9198862B2 (en) | 2005-07-22 | 2015-12-01 | Rubicon Research Private Limited | Dispersible tablet composition |
| RU2008124805A (ru) | 2005-11-21 | 2009-12-27 | Шеринг-Плоу Лтд. (CH) | Фармацевтические композиции, содержащие бупренорфин |
| US9757455B2 (en) | 2005-11-28 | 2017-09-12 | Johnson & Johnson Consumer Inc. | Oral therapeutic compound delivery system |
| US8435965B2 (en) | 2005-12-27 | 2013-05-07 | Lion Corporation | Composition for soft contact lens and adsorption suppressing method |
| WO2007103687A2 (en) | 2006-03-01 | 2007-09-13 | Tristrata, Inc. | Composition and method for topical treatment of tar-responsive dermatological disorders |
| WO2007103435A2 (en) | 2006-03-06 | 2007-09-13 | The Regents Of The University Of California | Bioavailable curcuminoid formulations for treating alzheimer's disease and other age-related disorders |
| US7767217B2 (en) | 2006-03-14 | 2010-08-03 | Foresight Biotherapeutics | Ophthalmic compositions comprising povidone-iodine |
| KR20090010953A (ko) | 2006-03-28 | 2009-01-30 | 자블린 파머슈티칼스 인코포레이티드 | 저 복용량의 비-스테로이드성 항염증성 약물 및 베타-사이클로덱스트린 제형 |
| US8580954B2 (en) * | 2006-03-28 | 2013-11-12 | Hospira, Inc. | Formulations of low dose diclofenac and beta-cyclodextrin |
| WO2008006216A1 (en) | 2006-07-14 | 2008-01-17 | Mistral Pharma, Inc. | Anti-inflammatory and cytoprotectant chronotherapy |
| CA2914170C (en) | 2006-09-08 | 2018-10-30 | Abbvie Bahamas Ltd. | Interleukin-13 binding proteins |
| CN105168186A (zh) | 2006-10-02 | 2015-12-23 | Apr应用制药研究股份公司 | 非粘膜粘着性膜剂型 |
| EP2511844B1 (en) | 2006-10-10 | 2015-08-12 | XRpro Sciences, Inc. | X-ray microscope |
| FI20065800A0 (fi) | 2006-12-13 | 2006-12-13 | Glykos Finland Oy | Polyvalentit biokonjugaatit |
| EP2120962A1 (en) | 2006-12-18 | 2009-11-25 | Allergan, Inc. | Methods and compositions for treating gastrointestinal disorders |
| US20100166870A1 (en) | 2006-12-21 | 2010-07-01 | The University Of Western Australia | Method for Coating Nanoparticles |
| WO2008115572A1 (en) | 2007-03-21 | 2008-09-25 | Theraquest Biosciences, Inc. | Methods and compositions of nsaids |
| EP1974751A1 (en) | 2007-03-26 | 2008-10-01 | The Jordanian Pharmaceutical Manufacturing Co. | Formulations for non-steroidal anti-inflammatory drugs |
| CN101686681B (zh) | 2007-04-27 | 2015-04-01 | 锡德克斯药物公司 | 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法 |
| WO2008133982A2 (en) | 2007-04-27 | 2008-11-06 | Lectec Corporation | Adhesive patch with aversive agent |
| US7662858B2 (en) | 2008-05-23 | 2010-02-16 | Aaipharma, Inc. | Method of treating post-surgical acute pain |
| MY166036A (en) * | 2011-07-20 | 2018-05-21 | Hospira Inc | Methods of treating pain |
-
2007
- 2007-03-22 US US11/689,931 patent/US8580954B2/en not_active Expired - Fee Related
- 2007-03-22 KR KR1020087024795A patent/KR20080112285A/ko not_active Ceased
- 2007-03-22 AU AU2007230716A patent/AU2007230716B2/en not_active Ceased
- 2007-03-22 JP JP2009503166A patent/JP5823093B2/ja not_active Expired - Fee Related
- 2007-03-22 MX MX2008012495A patent/MX2008012495A/es active IP Right Grant
- 2007-03-22 BR BRPI0709409-4A patent/BRPI0709409A2/pt not_active Application Discontinuation
- 2007-03-22 EP EP07759156A patent/EP2004203A4/en not_active Ceased
- 2007-03-22 EP EP20120164654 patent/EP2522343A1/en not_active Withdrawn
- 2007-03-22 WO PCT/US2007/064678 patent/WO2007112272A2/en not_active Ceased
- 2007-03-22 CN CNA2007800115094A patent/CN101410123A/zh active Pending
- 2007-03-22 KR KR1020167006852A patent/KR20160033796A/ko not_active Ceased
- 2007-03-22 CN CN201210342041XA patent/CN102846585A/zh active Pending
- 2007-03-22 KR KR1020177031515A patent/KR20170123724A/ko not_active Ceased
- 2007-03-22 EP EP20120164658 patent/EP2522344A1/en not_active Withdrawn
- 2007-03-22 CA CA 2647348 patent/CA2647348A1/en not_active Abandoned
- 2007-03-22 KR KR1020157010213A patent/KR20150050595A/ko not_active Ceased
- 2007-03-22 KR KR1020147007290A patent/KR20140038575A/ko not_active Ceased
-
2008
- 2008-09-17 IL IL194185A patent/IL194185A/en not_active IP Right Cessation
- 2008-09-22 ZA ZA2008/08115A patent/ZA200808115B/en unknown
-
2011
- 2011-05-12 US US13/106,697 patent/US8946292B2/en active Active
-
2012
- 2012-10-14 IL IL222432A patent/IL222432A/en not_active IP Right Cessation
-
2013
- 2013-10-10 US US14/051,021 patent/US20140107209A1/en not_active Abandoned
- 2013-10-17 JP JP2013216668A patent/JP6157305B2/ja not_active Expired - Fee Related
-
2014
- 2014-12-19 US US14/576,404 patent/US20150105467A1/en not_active Abandoned
-
2015
- 2015-12-10 JP JP2015241131A patent/JP6265964B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007230718B2 (en) | Formulations of low dose non-steroidal anti-inflammatory drugs and beta-cyclodextrin | |
| AU2007230716B2 (en) | Formulations of low dose diclofenac and beta-cyclodextrin | |
| Atkinson et al. | Pharmacokinetics and bioavailability of a fixed-dose combination of ibuprofen and paracetamol after intravenous and oral administration | |
| BR112013010829B1 (pt) | Omposição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação | |
| WO2020242543A1 (en) | Liquid pharmaceutical compositions of baclofen for oral administration | |
| CN101816643A (zh) | 含有双氯芬酸钠和对乙酰氨基酚的药物组合物 | |
| AU2012209035B2 (en) | Formulations of low dose diclofenac and beta-cyclodextrin | |
| WO2009089269A1 (en) | Methods of treating pain while minimizing adverse effects on platelet function | |
| US12168000B2 (en) | Methods of treating pain | |
| HK1180247A (en) | Formulations of low dose diclofenac and beta-cyclodextrin | |
| JP2005520856A (ja) | 貯蔵時に安定なエプレレノン製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |